We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.
CredibleMeds icon

4.6.9 by Azcert Inc


Apr 8, 2025

About CredibleMeds

Lists of drugs that prolong the QT interval & increase risk of heart arrhythmia

This CredibleMeds Mobile App supports the CredibleMeds.org website which maintains and posts lists of drugs in categories that reflect their ability to prolong the QT interval on the electrocardiogram and/or cause the life-threatening heart arrhythmia, torsades de pointes (TdP).

The CredibleMeds Mobile App was developed for patients, especially those with Congenital Long QT Syndrome (cLQTS), healthcare professionals and research scientists in order to provide them with ready access to the most up-to-date version of the CredibleMeds lists of drugs.

For healthcare professionals and research scientists, the QTdrugs Lists can be used to identify which drugs can cause QT prolongation or TdP.

The App also provides background information on the categories of drug risk and explains the relationship between QT prolongation and TdP.

For patients with Congenital Long QT Syndrome, the drugs and risk categories are described and designated separately as the list of Drugs to Avoid in cLQTS.

What's New in the Latest Version 4.6.9

Last updated on Apr 8, 2025

Minor Bug fixes and Therapeutic options added

Translation Loading...

Additional APP Information

Latest Version

Request CredibleMeds Update 4.6.9

Uploaded by

Lê Đạt

Requires Android

Android 7.0+

Available on

Get CredibleMeds on Google Play

Show More

CredibleMeds Screenshots

Also available for other platforms

Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.